Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm.
Business Model:
Revenue: $9.6M
Employees: 2-10
Rankings
Detailed Foresite Capital Information
Geographic Data
Address: 900 Larkspur Landing Circle
City: Larkspur
State: CA
Zip: 94939
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Twitter
Linkedin
Crunchbase
Metrics
4,452,860Website Global Rank
2,677Website Monthly Traffic
Twitter Followers
Description
Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.
Contact Phone:
+14158774887
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 6/2015 | Twist Bioscience | Series C | 37M |
| 5/2021 | Interline Therapeutics | Series A | 59.5M |
| 5/2020 | Kriya Therapeutics | Series A | 0 |
| 12/2018 | Genomics | Series B | 9.1M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 3/2021 | Genomics | Venture Round | 30M |
| 10/2020 | Sestina Bio | Seed Round | - |
| 6/2020 | Cue | Series C | 102.6M |
| 11/2019 | Genapsys | Series C | 90M |
| 4/2019 | HealthVerity | Series C | 25M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 7/2013 | Sequenta | Series C | 20M |
| 4/2020 | Cerevance | Series B | 65M |
| 9/2019 | Pharvaris | Series B | 66M |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 1/2020 | Element Biosciences | Series B | 80M |
| 1/2022 | Eikon Therapeutics | Series B | 0 |
| 3/2021 | Interline Therapeutics | Seed Round | 32.5M |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 6/2021 | HealthVerity | Series D | 100M |
| 6/2019 | Element Biosciences | Series A | 15M |
| 9/2016 | Arcus Biosciences | Series B | 70M |
| 7/2013 | Karyopharm Therapeutics | Series B | 19M |
| 6/2022 | Myome | Series B | 0 |
| 9/2014 | Ivantis | Series B | 25M |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 2/2023 | evonetix | Series B | 0 |
| 4/2023 | Foresight Diagnostics | Series B | 0 |
| 9/2017 | Replimune Group | Series B | 55M |
| 5/2020 | Mindstrong | Series C | 100M |
| 1/2021 | LifeMine Therapeutics | Series B | 0 |
| 3/2020 | evonetix | Series B | 30M |
| 11/2020 | SomaLogic | Series A | 0 |
| 11/2020 | Pharvaris | Series C | 80M |
| 6/2018 | Vaxcyte | Series C | 85M |
| 6/2020 | bit.bio | Series A | 41.5M |
| 6/2017 | Mindstrong | Series A | 14M |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 5/2021 | Aetion | Series C | 110M |
| 6/2021 | 23andMe | Post-IPO Equity | 250M |
| 12/2014 | 10X Genomics | Series B | 55.5M |
| 6/2018 | Mindstrong | Series B | 15M |
| 2/2018 | Generation Bio | Series B | 100M |
| 6/2020 | Detect | Series B | - |
| 5/2014 | Tarsa Therapeutics | Series B | 0 |
| 12/2020 | EverlyWell | Series D | 175M |
| 5/2021 | Eikon Therapeutics | Series A | 148M |
| 4/2014 | Intarcia Therapeutics | Venture Round | 0 |
| 6/2013 | WaveTec Vision | Series D | 11M |
| 9/2016 | Intarcia Therapeutics | Series E | 0 |
| 5/2022 | Kriya Therapeutics | Series C | 0 |
| 4/2018 | Kinnate Biopharma | Series A | 22M |
| 7/2021 | Kriya Therapeutics | Series B | 0 |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 4/2021 | Inscripta | Series E | 150M |
| 1/2018 | Juvenescence | Seed Round | 12.3M |
| 4/2014 | Nexvet | Series B | 31.5M |
| 6/2020 | DNAnexus | Series G | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 3/2020 | Keros Therapeutics | Series C | 0 |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 8/2021 | XinThera | Series B | 50M |
| 1/2015 | Aduro BioTech | Series D | 51.4M |
| 2/2018 | ORIC Pharmaceuticals | Series C | 50M |
| 12/2015 | ORIC Pharmaceuticals | Series B | 53M |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 4/2019 | Inscripta | Series C | 0 |
| 7/2020 | Olema Oncology | Series B | 54M |
| 9/2015 | Intellia Therapeutics | Series B | 0 |
| 2/2020 | ALX Oncology | Series C | 105M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 4/2021 | Tesseract Health | Series B | 0 |
| 5/2021 | Alumis | Series A | 70M |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 3/2020 | Vaxcyte | Series D | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 1/2021 | Affinivax | Series C | 226M |
| 4/2019 | Insitro | Series A | 100M |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 11/2022 | Detect | Series C | - |
| 6/2021 | Quantum SI | Post-IPO Equity | 425M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 1/2016 | Twist Bioscience | Series D | 61M |
| 2/2017 | Inscripta | Series B | 23M |
| 3/2015 | Aimmune Therapeutics | Series B | 80M |
| 12/2021 | Tasso | Series B | 0 |
| 9/2015 | AveXis | Series D | 65M |
| 2/2016 | 10X Genomics | Series C | 75M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 6/2021 | Element Biosciences | Series C | 276M |
| 2/2023 | Cerevance | Series B | 0 |
| 9/2018 | Fulcrum Therapeutics | Series B | 80M |
| 1/2020 | Generation Bio | Series C | 110M |
| 1/2018 | DNAnexus | Series E | 58M |
| 6/2018 | Decibel Therapeutics | Series C | 55M |
| 3/2022 | DNAnexus | Series H | 200M |
| 7/2020 | Tasso | Series A | 17M |
| 3/2014 | SAGE Therapeutics | Series C | 38M |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 2/2019 | DNAnexus | Series F | 68M |
| 1/2020 | PACT Pharma | Series C | 0 |
| 5/2020 | Insitro | Series B | 143M |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 7/2017 | Venatorx Pharmaceuticals | Series B | 42M |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 10/2022 | Folx Health | Series B | 0 |
| 1/2014 | Ivantis | Series B | 14M |
| 1/2022 | TenSixteen Bio | Equity | 40M |
| 3/2012 | Tarsa Therapeutics | Series B | 28M |
| 8/2019 | ORIC Pharmaceuticals | Series D | 0 |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 7/2020 | VelosBio | Series B | 137M |
| 12/2018 | Inscripta | Series C | 0 |
| 2/2018 | Inscripta | Series C | 55.5M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 10/2022 | Pleno | Series A | 0 |
| 3/2021 | Crossover Health | Series D | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 9/2016 | Peloton Therapeutics | Series D | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 12/2019 | Kinnate Biopharma | Series B | 74.5M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 4/2021 | Adagio Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 9/2021 | Mammoth Biosciences | Series D | 0 |
| 11/2020 | Mammoth Biosciences | Series C | 45M |
| 5/2022 | Mirvie | Series B | 0 |
| 11/2021 | bit.bio | Series B | 103M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 4/2023 | Foresight Diagnostics | Series B | 0 |
| 2/2023 | Cerevance | Series B | 0 |
| 2/2023 | evonetix | Series B | 0 |
| 11/2022 | Detect | Series C | - |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 10/2022 | Folx Health | Series B | 0 |
| 10/2022 | Pleno | Series A | 0 |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2022 | Myome | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
